Drug intelligence / Profile preview

MQI-231

Development stage: Preclinical
Lead developer: Mabqi
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MQI-231 is a preclinical-stage, pH-sensitive antibody-drug conjugate (ADC) being developed by Mabqi for the treatment of oncology indications. Designed using Mabqi's proprietary LiteMab Sense platform, MQI-231 features a conditionally active, pH-dependent antibody that preferentially binds to its target antigen within the acidic tumor microenvironment (TME) while showing minimal binding at physiological pH in healthy tissues. This tumor-selective binding mechanism is engineered to optimize the therapeutic index of the ADC by enhancing localized payload delivery and reducing off-tumor systemic toxicities. The specific biological target of MQI-231 remains undisclosed.

Beyond the preview

Go deeper on MQI-231.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MQI-231.

Explore the full profile